Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04563962 · ClinicalTrials.gov registry record · NA
Contingency Management for PrEP Adherence and/or Methamphetamine Use
A NA study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT04563962 is a NA study that has completed, run by University of California, Los Angeles. The registered enrollment target is 20 participants.
The verdict
NCT04563962, a NA study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
Use of crystal methamphetamine (MA) leads to changes in sexual risk behavior, adherence to HIV prevention tools, immune response to infection, and tissue inflammation that collectively increase risk for HIV transmission among MA-using men who have sex with men (MSM), their sexual partners, and their networks. Contingency Management (CM) offers a behavioral modification tool helpful for reducing frequency of MA use, but the effects of CM on the behavioral and biological factors that promote HIV transmission in MSM networks have only been partially evaluated. The intersection of substance use, sexual risk behavior, and HIV transmission in MSM networks presents a critical problem for contemporary HIV prevention as HIV-uninfected MSM who use MA have a 16%-33% greater risk for HIV infection, while only approximately 50% of HIV-infected MA-using MSM achieve and maintain an undetectable viral load. The investigators propose to compare two different CM models to integrate substance use treatment with HIV prevention among MA-using MSM: 1) Traditional CM targeted to MA abstinence and 2) Allternative CM based on ARV adherence.
Interventions
- BEHAVIORAL Contingency Management-ART
- BEHAVIORAL Contingency Management-Methamphetamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-03-15 |
| Est. Completion | 2021-08-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04563962
The ClinicalTrials.gov registry entry for NCT04563962 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Contingency Management-ART is the first listed.
NCT04563962 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04563962 about?
NCT04563962 is a clinical study titled "Contingency Management for PrEP Adherence and/or Methamphetamine Use". Use of crystal methamphetamine (MA) leads to changes in sexual risk behavior, adherence to HIV prevention tools, immune response to infection, and tissue inflammation that collectively increase risk for HIV transmission among MA-using men who have sex with men (MSM), their sexual partners, and their...
What is the current status of trial NCT04563962?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2021-03-15. Estimated completion is 2021-08-31.
What interventions are being tested in trial NCT04563962?
The interventions under investigation include: Contingency Management-ART (BEHAVIORAL), Contingency Management-Methamphetamine (BEHAVIORAL).
Who is sponsoring clinical trial NCT04563962?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.